Exacerbation of myasthenia gravis after zoledronic acid and denosumab: a novel clinical observation with therapeutic implications Authors: Stefania Canneva, Anna De Giovanni, Felicita Pagella, Carlo Trompetto, Marina Grandis, Laura Mori Published: 2026 ABSTRACT BackgroundPatients affected by myasthenia gravis undergoing long-term corticosteroid therapy have an increased risk of osteoporosis and fragility fractures, frequently requiring antiresorptive treatment. Although bisphosphonates and denosumab are generally well tolerated, rare cases of onset or worsening of myasthenic symptoms following bisphosphonate therapy have been reported, while no cases associated with denosumab have been described to date.Case presentationWe report the case of a 78-year-old woman with long-standing, stable myasthenia gravis who developed a significant exacerbation of myasthenic symptoms following intravenous infusion of zoledronic acid and, subsequently, after a single administration of denosumab. In both instances, a temporary increase in corticosteroid therapy was required. Following these events, antiresorptive agents were discontinued, and supplementation with cholecalciferol was maintained.ConclusionTo our knowledge, this represents the first reported case of exacerbation of myasthenic symptoms following denosumab administration. Background Myasthenia gravis (MG) is a rare, chronic autoimmune disorder affecting the neuromuscular junction, clinically characterized by fluctuating, activity-induced skeletal muscle weakness that typically improves with rest [1]. MG often requires long-term immunosuppressive therapy, which may result in significant systemic side effects, including adverse effects on bone metabolism [2]. In MG, several intersecting pathophysiological and iatrogenic factors contribute to impaired bone health. These include reduced mechanical loading due to physical inactivity, hypovitaminosis D related to reduced sun exposure, possible dysphagia leading to malnutrition, and, most critically, chronic use of glucocorticoids and other immunosuppressive agents known to negatively affect bone remodeling [3]. Therefore, patients with MG should be carefully monitored for bone health. In particular, in individuals at high fracture risk and receiving long-term corticosteroid therapy, initiation of osteoprotective treatment should be considered even for primary prevention. Bisphosphonates are the first-line agents for glucocorticoid-induced osteoporosis, while denosumab is generally reserved for patients who are intolerant to bisphosphonates or have medical contraindications to their use. Here, we present a case of particular clinical interest involving a patient with long-standing stable MG who developed worsening myasthenic symptoms following administration of both zoledronic acid and denosumab. Case presentation The patient was a 78-year-old woman affected by MG since 2009, diagnosed after the onset of diplopia and skeletal muscle weakness. At the time of coming to our attention the patient was followed at the Neurology outpatient clinics of Azienda Ospedaliera Metropolitana Regione Liguria (AOM) Plesso Ospedale Policlinico San Martino IRCCS in Genoa and was receiving prednisone (5 mg/day) and pyridostigmine (60 mg four times daily), with good clinical control of her myasthenic disease. Data about previous treatments was retrospectively collected from 2022 to the first visit at our Osteoporosis Center at AOM Regione Liguria Plesso Ospedale Policlinico San Martino IRCCS in October 2024. In December 2022, at another center, she received a single intravenous dose of zoledronic acid (5 mg) due to progressive worsening of bone mineral density values. This treatment was followed by a deterioration of her myasthenic condition after four weeks following the administration of zoledronic acid, with upper limb weakness and dysphagia, requiring an increase in corticosteroid therapy, which led to regression of the myasthenic exacerbation in approximately four weeks. Biochemical parameters of bone metabolism before and after zoledronate injection are not available because the patient was treated and monitored in another osteoporosis centre. Laboratory tests performed in September 2024 showed normal calcium and phosphate levels, adequate 25-hydroxyvitamin D levels, and mildly elevated parathyroid hormone levels (calcium 9.8 mg/dL, phosphate 4.0 mg/dL, 25(OH)D 52 ng/mL, CTX 0.250 ng/mL, PTH 106 pg/mL). The patient was subsequently referred to our Osteoporosis Center in October 2024 for further osteometabolic assessment. Dual-energy X-ray absorptiometry (GE HealthCare – Lunar) performed in October 2024 showed lumbar and femoral osteopenia: lumbar spine (L1–L4) T-score − 1.5 (range − 0.1 to − 2.4), femoral neck T-score − 2.0 (range − 0.1 to − 2.4), and total hip T-score − 1.9 (range − 0.1 to − 2.4). A thoracolumbar spine radiograph performed in October 2024 showed no vertebral fractures. Considering that risk factors for osteoporosis included chronic corticosteroid therapy, family history of osteoporosis without fragility fractures, and a tendency to falls increasing the fracture risk, treatment with denosumab (60 mg subcutaneously every six months) was initiated in November 2024, in association with cholecalciferol (25,000 IU monthly), which, at present, the patient is still taking. Risk of major osteoporotic fracture at 10 years was calculated using DEFRAcalc and was 28%, confirming the need to start antiresorptive therapy (https://defra-osteoporosi.it). Biochemical parameters of bone metabolism after denosumab injection are not available. At follow-up in April 2025 our Osteoporosis Center, the patient reported worsening myasthenic symptoms occurring approximately six weeks after the denosumab injection, including head drop tendency, dysarthria, sialorrhea, cervical pain, and muscle cramps in the lower limbs. Urgent neurological evaluation was performed at Neurology outpatient clinics of AOM Regione Liguria Plesso Ospedale Policlinico San Martino IRCCS, 48 h after reporting symptoms, which confirmed disease exacerbation, requiring an immediate increase in corticosteroid therapy (prednisone 10/7.5 mg on alternate days). The myasthenic symptoms gradually resolved over the course of one month. Laboratory tests performed in March 2025 confirmed stable calcium (9.7 mg/dL) and phosphate (4.1 mg/dL) levels, reduced 25-hydroxyvitamin D levels (32 ng/mL), and progressive normalization of parathyroid hormone levels (63 pg/mL). Given the absence of fragility fractures and the progressive reduction of corticosteroid dosage, a shared decision was made with the patient to discontinue antiresorptive therapy. Cholecalciferol supplementation was increased to 25,000 IU every 15 days, along with lifestyle recommendations including regular physical activity, adequate sun exposure, and appropriate dietary calcium intake. Reports of other electrolytes (Na/K, Mg, Ca, Phosphate, the routine relevant investigations such as the real function, Complete blood count, as well as myasthenic-specific anti-nicotinic antibodies) were not available during each myasthenic exacerbation. At subsequent follow-up (October 2025) our Osteoporosis Center, the patient showed stable neurological status despite further corticosteroid tapering, and spinal radiographs revealed no fractures. Therefore, supplementation with cholecalciferol alone was continued. The DEXA scan performed in April 2026 showed stability of bone mineral density, still within the osteopenic range (Fig. 1).Fig. 1Timeline of antiresorptive treatments and subsequent exacerbations of myasthenic symptoms in the reported patient Timeline of antiresorptive treatments and subsequent exacerbations of myasthenic symptoms in the reported patient Discussion and conclusions It is well established that certain drugs acting at the neuromuscular junction may induce or worsen myasthenic symptoms through presynaptic, postsynaptic, or indirect mechanisms (Table 1). Isolated cases reported in the literature suggest a possible association between bisphosphonates therapy and exacerbation of MG.Table 1List of drugs to avoid in myasthenia gravis Table 1List of drugs to avoid in myasthenia gravis List of drugs to avoid in myasthenia gravis Palin et al. described a case of a 67-year-old woman who developed MG following intravenous pamidronate therapy for hypercalcemia secondary to parathyroid adenoma [4]. Raja et al. reported the onset of ocular myasthenia in an 81-year-old woman after treatment with risedronate (35 mg weekly) for osteoporosis [5]. Kesikburun et al. described a 24-year-old man with MG who experienced worsening myasthenic symptoms during treatment with alendronate (70 mg weekly); notably, these symptoms did not recur after switching to another bisphosphonate (intravenous ibandronate 3 mg every three months) [6]. Conversely, several studies involving larger patient cohorts did not report clinical exacerbations in MG patients treated with oral bisphosphonates [7–10]. Based on the available evidence, neither zoledronic acid nor denosumab appears to exert a direct effect on the neuromuscular junction. Zoledronic acid infusion has been associated with the development of acute hypocalcemia and hypophosphatemia, even at doses used for osteoporosis. These changes might explain the myasthenic worsening [11]. Similarly, these parameters are expected after Densoumab injection as well. In particular, denosumab has been associated with hypocalcemia following administration in a substantial proportion of patients [12]. Although serum calcium levels were not available in our case, precluding definitive confirmation, the temporal association and the well-established effects of these agents on calcium homeostasis support the hypothesis that hypocalcemia may have contributed to the exacerbation of myasthenic symptoms. Taken together, these findings suggest that such worsening is unlikely to result from a direct pharmacological effect on the neuromuscular junction, but rather from ionic disturbances leading to impaired neuromuscular transmission. In the present case, the patient developed worsening myasthenic symptoms after exposure to two antiresorptive agents with distinct mechanisms of action: zoledronic acid, an inhibitor of osteoclastic activity, and denosumab, a monoclonal antibody targeting RANKL. This combination makes the case particularly noteworthy, suggesting that, albeit rare, an individual susceptibility may predispose to adverse neuromuscular responses to different classes of antiresorptive drugs. To our knowledge, this is the first documented case of MG exacerbation following denosumab administration, a drug generally considered to be well tolerated. This case highlights the importance of individualized fracture risk assessment in patients with MG receiving long-term corticosteroid therapy and suggests caution in the use of antiresorptive agents in this population. Further studies are needed to elucidate the underlying pathophysiological mechanisms and to define safe and effective strategies for managing bone metabolism in patients with MG.